Fusen Pharmaceutical Company Limited (HKG:1652)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.9300
+0.0400 (4.49%)
At close: Feb 13, 2026
Market Cap687.55M +47.6%
Revenue (ttm)264.08M -43.4%
Net Income-191.74M
EPS-0.26
Shares Out739.30M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,482,000
Average Volume499,250
Open0.8900
Previous Close0.8900
Day's Range0.8900 - 0.9700
52-Week Range0.2350 - 1.7500
Beta0.13
RSI78.77
Earnings DateMar 27, 2026

About HKG:1652

Fusen Pharmaceutical Company Limited, an investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. The company’s product portfolio includes Shuanghuanglian oral solutions and Shuanghuanglian injections; Sanhuang tablet; heat-clearing and detoxicating oral solutions; nicardipine hydrochloride injections; and other products. It also offers small and large volume injections, oral liquids, tablets, capsules, granules, traditional Chinese medicine extracts, and chemical sy... [Read more]

Sector Healthcare
Founded 2003
Employees 1,045
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1652
Full Company Profile

Financial Performance

In 2024, HKG:1652's revenue was 326.03 million, a decrease of -42.36% compared to the previous year's 565.61 million. Losses were -188.78 million, 420.4% more than in 2023.

Financial numbers in CNY Financial Statements